Skip to main content
Equibles
AHR logo

AHR · American Healthcare REIT, Inc. · Metrics

Track AHR — free

Use AHR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AHR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.78 -0.86 (-1.47%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$13.41B
Shares
232.07M
Volume · Nov 13 2.58M Avg daily vol (3M) 3.1M

AHR metrics

89 of 129 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$57.78
Market cap
$13.41B

Price action

23 metrics
Price change (1W)
-0.2%
Price change (30D)
+9.0%
Price change (3M)
+6.4%
Price change (6M)
+17.1%
Price change (YTD)
+22.8%
Price change (1Y)
+19.8%
Trailing year
Price change (5Y)
—
52-week high
$59.39
52-week low
$45.69
Change from 52-week high
-2.7%
Change from 52-week low
+26.5%
Annualized volatility
26.5%
Annualized volatility (3M)
24.1%
Implied volatility (30D)
41.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.0
RSI (14D)
62.6
Price vs SMA 50
+8.2%
Price vs SMA 200
+11.2%
Avg volume (3M)
3.10M
Relative volume
0.8
Average dollar volume
$166.77M

Company

3 metrics
Sector
Real Estate
Industry
REIT - Healthcare Facilities
Shares outstanding
232.07M

Valuation

14 metrics
P / FFO
37.4×
Company-stated · TTM · reciprocal yield 2.7%
P / AFFO
—
P / E (TTM)
115.6
Trailing earnings · reciprocal yield 0.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.0×
reciprocal yield 19.9%
P / book
2.4
reciprocal yield 41.3%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
31.8
reciprocal yield 3.1%
Earnings yield
0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
102.5×
reciprocal yield 1.0%
P / E historical average (5Y)
102.5×
reciprocal yield 1.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
1.7%
Trailing 12 months
Payout ratio
193.2%
Shareholder yield
—
Dividend / share (TTM)
$1.00
Dividend growth YoY
+0.0%
Dividend growth streak
0
Last ex-dividend
2026-09-30

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-06

Profitability

9 metrics
Gross margin
22.1%
Operating margin
20.2%
Trailing 12 months
Net margin
3.6%
Gross profit (TTM)
$589.22M
Operating profit (TTM)
$539.12M
Net income (TTM)
$96.31M
Trailing 12 months
Diluted EPS (TTM)
$0.50
FCF margin
—
Effective tax rate
-2.3%

Per share

13 metrics
FFO per diluted share
—
AFFO per diluted share
—
Revenue per diluted share (TTM)
$13.73
Gross profit per diluted share (TTM)
$3.02
Operating profit per diluted share (TTM)
$2.76
EBITDA per diluted share (TTM)
$4.21
Net income per diluted share (TTM)
$0.49
Operating cash flow per diluted share (TTM)
$2.12
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.13
Book value per share
$17.86

Growth

11 metrics
Revenue growth YoY
+29.5%
Year over year
Net income growth YoY
-44.2%
Revenue (TTM)
$2.67B
Trailing 12 months
EPS growth YoY
-57.6%
Shares change YoY
+28.2%
Year over year · more shares
Revenue CAGR (3Y)
+17.0%
Revenue CAGR (5Y)
+16.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
+53.1%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
1.7%
Return on assets
1.3%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
$824.50M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
7.2
Net debt / EBITDA
-0.3
Return on invested capital
—
Trailing 12 months
Net cash
$222.77M
Latest balance sheet
Cash & equivalents
$222.77M
Total assets
$7.61B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$421.74M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$25.36M
R&D / revenue
—
Stock compensation / revenue
0.9%

Ownership (13F)

9 metrics
13F filers
577
13F filer change QoQ
+52
Institutional ownership
97.2%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+29.4%
Holder tenure
6.8
Price vs estimated holder cost
+44.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.9%

Short interest

3 metrics
Short interest
14.5%
Latest settlement · 10.3 days to cover
Days to cover
10.3d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$337,170
Insider-sentiment score
42 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1632970 CUSIP 398182303 13F (30d) 477 filings 438 filers Visit website Investor relations